The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
March 7th 2024
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Patients With ALL Have High Readmission Risk Post Chemotherapy, but Hospitals Can Change That
November 5th 2020Many patients with acute lymphoblastic leukemia (ALL) who undergo chemotherapy end up back in the hospital within 30 days. A new study points out the reasons and opportunities for prevention.
Read More
Dr Michael Green Explains the Link Between Monocyte-Like Cells, Neurotoxicity After CAR T Therapy
November 3rd 2020Immune-associated neurotoxicity in patients following chimeric antigen receptor (CAR) T-cell therapy may be due to monocyte-like cells in infusion products, explained Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.
Watch
Prior Malignancy Linked to Risk of Secondary Malignancy in Follicular Lymphoma
October 29th 2020Previous research has found a link between a prior malignancy and secondary primary malignancy risk in patients with multiple myeloma. A new study suggests a similar association in follicular lymphoma.
Read More
Dr Michael Green Discusses Understanding Patient Response to CAR T-Cell Therapy
October 23rd 2020Chimeric antigen receptor (CAR) T-cell therapy does not always lead to a durable response, and we are trying to figure out why, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.
Watch
Dual US, China Approval Process for Zanubrutinib Shows Regulatory Differences
October 7th 2020The process of approving a new therapy for relapsing and/or remitting mantle cell lymphoma therapy got off to a faster start in China, but United States regulators caught up and approved the drug first.
Read More
Case Report: Ibrutinib Might Protect Against Acute Lung Injury in Patients With CLL, COVID-19
October 2nd 2020A patient with chronic lymphocytic leukemia (CLL) was continued on ibrutinib even after developing severe coronavirus disease 2019 (COVID-19). He successfully overcame the infection.
Read More
HSCT Viable for Children With Nonremission Acute Lymphoblastic Leukemia
September 30th 2020Research into children and adolescents with nonremission acute lymphoblastic leukemia (ALL) has been sparse, but a new analysis suggests that allogeneic hematopoietic stem cell transplantation is a good fit for some patients.
Read More
TKI Leads to Superior Outcomes in ALL With an ABL-Class Fusion, Study Says
September 23rd 2020Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to a new study.
Read More
Researchers Leverage p53 Expression to Identify TP53 Missense Mutations in MCL
August 21st 2020Reporting on their findings in the British Journal of Haematology, researchers have used immunohistochemistry (IHC) to leverage p53 expression as an identifier of mantle cell lymphoma (MCL) patients carrying mutations in tumor protein p53 (TP53), an indicator of poor prognosis in the disease.
Read More
CLL Experts Favor Social Distancing, but Vary on Treatment Continuation Amid Pandemic
July 24th 2020Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid the pandemic agreed with social distancing, but were cautious about universal testing and treatment continuation.
Read More